Revenue + Forward P/E
Protagonist Therapeutics, Inc. (PTGX) quarterly revenue and forward P/EForward P/E: 58.5x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$9.85B
Enterprise value
$8.53B
P/E ratio (TTM)
-75.16x
P/S ratio (TTM)
117.60x
P/B ratio
13.45x
EV/Sales
115.11x
EV/EBITDA
-74.84x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$46.02M
Gross profit (TTM)
$44.79M
Operating income (TTM)
$-158.13M
EBITDA (TTM)
$-128.09M
Net income (TTM)
$-130.15M
Free cash flow (TTM)
$56.08M
Margins & returns
Gross margin
99.45%
Operating margin
-192.36%
Profit margin
-154.88%
Return on equity
-17.76%
Return on assets
-16.45%
Per-share metrics
EPS (TTM)
-$1.76
Dividend yield
0.00%
Beta
1.79
Capital structure
Cash & equivalents
$128.39M
Total debt
$10.32M
Net debt
$-118.07M
Shares outstanding
64.31M
Financial health
Current ratio
12.71
Debt / equity
0.02
Debt / assets
0.02
Interest coverage
-
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.14T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.80B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.20B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.07B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.41B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $9.85B | -75.16x | 117.60x | -74.84x | - |